Tebotelimab — Investigational Agent
Bispecific Antibody · Phase 2/3 · MacroGenics
Mechanism of Action
Tetravalent bispecific DART antibody that co-blocks the checkpoint receptors PD-1 and LAG-3 on T cells, restoring exhausted T-cell function; studied with HER2-directed agents in gastric cancer.
Investigational Indications
- HER2-positive gastric/gastroesophageal junction adenocarcinoma
- Other advanced solid tumors